Golubieski will begin the CFO role on November 4, the company announced in a statement.
The appointment “comes at a time of significant opportunity and growth for BDSI,” said Jeff Bailey, the CEO for BioDelivery Sciences International, in a statement. “I know first-hand the impact John can bring to our team as John has served the role as my CFO three times previously. ” His very well-rounded business and financial expertise will be important as we drive results and realize our mission to improve patient lives.”
Bailey added that Golubieski previously served as his CFO three times previously.
Golubieski’s career includes 16 years of service as Bristol-Myers Squibb, a role as senior vice president of finance as King Pharmaceuticals prior to the acquisition of the company by Pfizer, CFO at Fougera prior to the company’s acquisition by Novartis, and as interim CFO at Lantheus Medical Imaging which would later file for an initial public offering.
Most recently, Golubieski was the CFO of IlluminOss, an orthopedic company that was acquired last year by a private equity firm, according to a statement issued by BioDelivery Sciences International.
“I am thrilled to join BDSI during this exciting time of growth for the company,” said John Golubieski in a statement. “With the expanding portfolio and a clear focus on improving patient lives, I am honored to be part of this mission and look forward to working with the team to drive continued success.”
The company’s current CFO, Terry Coelho, will remain with the company until November 3, the company statement noted. Coelho was promoted to executive vice president in February 2021 and recently was appointed to the Board of Directors at AzurRx BioPharma.
Bailey said in a statement that Coelho planned to take another opportunity.